Literature DB >> 14769133

Telomere maintenance in childhood primitive neuroectodermal brain tumors.

Domenico Didiano1, Tarek Shalaby, Doris Lang, Michael A Grotzer.   

Abstract

Primitive neuroectodermal tumors (PNETs), including medulloblastoma (PNET/MB) and supratentorial PNET (sPNET), are the most common malignant brain tumors of childhood. The stabilization of telomere lengths by telomerase activation is an important step in carcinogenesis and cell immortalization. Epigallocatechin gallate (EGCG), the major polyphenol in green tea, is a telomerase inhibitor with antiproliferative and anticarcinogenic effects against different types of cancer. In this study, we used real-time reverse transcriptase-polymerase chain reaction to measure the mRNA expression of the human telomerase reverse transcriptase (hTERT) in 50 primary PNET samples (43 PNET/MB, 7 sPNET), 14 normal human brain samples, and 6 human PNET cell lines. Compared to normal human cerebellum, 38/50 (76%) primary PNET samples had >or= 5-fold upregulated hTERT mRNA expression. We then examined PNET cell lines for telomerase activity using a quantitative telomeric repeat amplification protocol (TRAP), and for telomere length using terminal restriction fragment analysis. While a positive correlation between hTERT mRNA expression and telomerase activity was detected in PNET cell lines, no correlation was found between telomerase activity and telomere length. Treatment of PNET cell lines with EGCG resulted in a dose-dependent inhibition of telomerase activity at micromolar levels. Although EGCG displayed strong proliferation inhibitory effects against TRAP-positive PNET cell lines, it had no significant effect against TRAP-negative D425 cells. These results provide evidence for a possible role of telomerase in the pathogenesis of most PNETs and indicate that subsets of PNETs maintain telomere length by alternative mechanisms. Inhibition of telomerase function represents a novel experimental therapeutic strategy in childhood PNETs that warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14769133      PMCID: PMC1871965          DOI: 10.1215/S1152851703000176

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  50 in total

Review 1.  An overview of real-time quantitative PCR: applications to quantify cytokine gene expression.

Authors:  A Giulietti; L Overbergh; D Valckx; B Decallonne; R Bouillon; C Mathieu
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma.

Authors:  T J Zuzak; D F Steinhoff; L N Sutton; P C Phillips; A Eggert; M A Grotzer
Journal:  Eur J Cancer       Date:  2002-01       Impact factor: 9.162

Review 3.  Telomerase in brain tumors.

Authors:  M L Falchetti; L M Larocca; R Pallini
Journal:  Childs Nerv Syst       Date:  2002-02-23       Impact factor: 1.475

Review 4.  Cancer prevention with green tea and monitoring by a new biomarker, hnRNP B1.

Authors:  H Fujiki; M Suganuma; S Okabe; E Sueoka; N Sueoka; N Fujimoto; Y Goto; S Matsuyama; K Imai; K Nakachi
Journal:  Mutat Res       Date:  2001-09-01       Impact factor: 2.433

Review 5.  Alternative lengthening of telomeres in mammalian cells.

Authors:  Jeremy D Henson; Axel A Neumann; Thomas R Yeager; Roger R Reddel
Journal:  Oncogene       Date:  2002-01-21       Impact factor: 9.867

Review 6.  Telomere and telomerase in oncology.

Authors:  Jiao Mu; Li Xin Wei
Journal:  Cell Res       Date:  2002-03       Impact factor: 25.617

7.  Absorption and distribution of tea catechin, (-)-epigallocatechin-3-gallate, in the rat.

Authors:  K Nakagawa; T Miyazawa
Journal:  J Nutr Sci Vitaminol (Tokyo)       Date:  1997-12       Impact factor: 2.000

8.  Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.

Authors:  M A Grotzer; A Eggert; T J Zuzak; A J Janss; S Marwaha; B R Wiewrodt; N Ikegaki; G M Brodeur; P C Phillips
Journal:  Oncogene       Date:  2000-09-21       Impact factor: 9.867

9.  Rhodacyanine dye MKT-077 inhibits in vitro telomerase assay but has no detectable effects on telomerase activity in vivo.

Authors:  Renu Wadhwa; Lorel Colgin; Tomoko Yaguchi; Kazunari Taira; Roger R Reddel; Sunil C Kaul
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

10.  Inhibitory activity of green and black tea in a free radical-generating system using 2-amino-3-methylimidazo[4,5-f]quinoline as substrate.

Authors:  N Hasaniya; K Youn; M Xu; J Hernaez; R Dashwood
Journal:  Jpn J Cancer Res       Date:  1997-06
View more
  10 in total

1.  Targeting human telomerase for cancer therapeutics.

Authors:  Lionel Guittat; Patrizia Alberti; Dennis Gomez; Anne De Cian; Gaëlle Pennarun; Thibault Lemarteleur; Chafke Belmokhtar; Rajaa Paterski; Hamid Morjani; Chantal Trentesaux; Eliane Mandine; François Boussin; Patrick Mailliet; Laurent Lacroix; Jean-François Riou; Jean-Louis Mergny
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

2.  A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.

Authors:  Ralph Salloum; Trent R Hummel; Shiva Senthil Kumar; Kathleen Dorris; Shaoyu Li; Tong Lin; Vinay M Daryani; Clinton F Stewart; Lili Miles; Tina Young Poussaint; Charles Stevenson; Stewart Goldman; Girish Dhall; Roger Packer; Paul Fisher; Ian F Pollack; Maryam Fouladi; James Boyett; Rachid Drissi
Journal:  J Neurooncol       Date:  2016-06-27       Impact factor: 4.130

3.  The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells.

Authors:  Alessandra Rossi; Giuseppe Russo; Andrew Puca; Raffaele La Montagna; Mariella Caputo; Eliseo Mattioli; Massimo Lopez; Antonio Giordano; Francesca Pentimalli
Journal:  Int J Cancer       Date:  2009-07-01       Impact factor: 7.396

4.  Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.

Authors:  Lee Ridley; Ruman Rahman; Marie-Anne Brundler; David Ellison; James Lowe; Keith Robson; Emma Prebble; Inga Luckett; Richard J Gilbertson; Sheila Parkes; Vikki Rand; Beth Coyle; Richard G Grundy
Journal:  Neuro Oncol       Date:  2008-08-13       Impact factor: 12.300

5.  Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics.

Authors:  Alma Ortiz-Plata; Martha Lilia Tena Suck; Mario López-Gómez; Alfonso Heras; Aurora Sánchez García
Journal:  J Neurooncol       Date:  2007-03-15       Impact factor: 4.130

6.  Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.

Authors:  Kathleen Dorris; Matthew Sobo; Arzu Onar-Thomas; Eshini Panditharatna; Charles B Stevenson; Sharon L Gardner; Mariko D Dewire; Christopher R Pierson; Randal Olshefski; Sandra A Rempel; Stewart Goldman; Lili Miles; Maryam Fouladi; Rachid Drissi
Journal:  J Neurooncol       Date:  2014-01-30       Impact factor: 4.130

7.  Epigallocatechin gallate inhibits the growth and promotes the apoptosis of bladder cancer cells.

Authors:  Chenchen Feng; Yatfaat Ho; Chuanyu Sun; Guowei Xia; Qiang Ding; Bin Gu
Journal:  Exp Ther Med       Date:  2017-08-21       Impact factor: 2.447

8.  Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir.

Authors:  Marieke Gringmuth; Jenny Walther; Sebastian Greiser; Magali Toussaint; Benjamin Schwalm; Marcel Kool; Rolf-Dieter Kortmann; Annegret Glasow; Ina Patties
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

9.  A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).

Authors:  Patrick A Thompson; Rachid Drissi; Jodi A Muscal; Eshini Panditharatna; Maryam Fouladi; Ashish M Ingle; Charlotte H Ahern; Joel M Reid; Tong Lin; Brenda J Weigel; Susan M Blaney
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

10.  RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells.

Authors:  André O von Bueren; Tarek Shalaby; Christoph Oehler-Jänne; Lucia Arnold; Duncan Stearns; Charles G Eberhart; Alexandre Arcaro; Martin Pruschy; Michael A Grotzer
Journal:  BMC Cancer       Date:  2009-01-10       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.